• Cabaletta Bio highlighted rese-cel (CABA-201), an autologous CD19 CAR T program in autoimmune disease, with additional preconditioning-free clinical data expected through 2026.
• Complete Phase 1/2 readouts in systemic sclerosis and lupus are expected in 1H26; myasthenia gravis data were presented at AAN.
• Myositis strategy centers on a 17-patient single-arm registrational cohort with a planned 2027 BLA submission; primary endpoint is moderate total improvement score off immunomodulators at 16 weeks.
• Across first 40 patients dosed with preconditioning, 95% had no CRS or Grade 1 CRS; 95% had no ICANS, supporting an outpatient administration profile.
• Company cited a USD 150 million raise that extends cash runway into mid-2027, funding preconditioning-free development, automated manufacturing with Cellares, myositis BLA work, and initiation of a second pivotal indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.